NASDAQ:GTH

Genetron Stock Forecast, Price & News

$14.35
+0.22 (+1.56 %)
(As of 08/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.85
$14.47
50-Day Range
$13.00
$22.06
52-Week Range
$9.03
$31.54
Volume273,979 shs
Average Volume356,904 shs
Market Capitalization$1.28 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.66
30 days | 90 days | 365 days | Advanced Chart
Receive GTH News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetron and its competitors with MarketBeat's FREE daily newsletter.


Genetron logo

About Genetron

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of hepatocellular carcinoma. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1 and TERT gene assays for glioma; Genetron S5 platform, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; and Genetron S2000 platform, a production-scale sequencer. In addition, the company develops ctDNA lung cancer assay for mutations in the epidermal growth factor receptor gene. Further, it offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.02 out of 5 stars

Medical Sector

1170th out of 1,311 stocks

Medical Laboratories Industry

27th out of 29 stocks

Analyst Opinion: 3.5Community Rank: 1.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Genetron (NASDAQ:GTH) Frequently Asked Questions

Is Genetron a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genetron in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Genetron stock.
View analyst ratings for Genetron
or view top-rated stocks.

What stocks does MarketBeat like better than Genetron?

Wall Street analysts have given Genetron a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Genetron wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Genetron?

Genetron saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 448,200 shares, an increase of 19.0% from the June 30th total of 376,500 shares. Based on an average daily volume of 275,200 shares, the short-interest ratio is currently 1.6 days. Currently, 0.6% of the shares of the stock are short sold.
View Genetron's Short Interest
.

When is Genetron's next earnings date?

Genetron is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Genetron
.

How were Genetron's earnings last quarter?

Genetron Holdings Limited (NASDAQ:GTH) announced its quarterly earnings results on Sunday, May, 23rd. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.10. The company had revenue of $14.05 million for the quarter. Genetron had a negative trailing twelve-month return on equity of 16.41% and a negative net margin of 666.57%.
View Genetron's earnings history
.

What guidance has Genetron issued on next quarter's earnings?

Genetron updated its FY 2021 earnings guidance on Tuesday, June, 22nd. The company provided EPS guidance of $- for the period. The company issued revenue guidance of $93.87 million-95.39 million, compared to the consensus revenue estimate of $97.31 million.

What price target have analysts set for GTH?

1 brokerages have issued twelve-month target prices for Genetron's shares. Their forecasts range from $19.00 to $19.00. On average, they anticipate Genetron's stock price to reach $19.00 in the next year. This suggests a possible upside of 32.4% from the stock's current price.
View analysts' price targets for Genetron
or view top-rated stocks among Wall Street analysts.

Who are Genetron's key executives?

Genetron's management team includes the following people:
  • Dr. Wei-Wu He, Co-Founder & Chairman (Age 56)
  • Mr. Sizhen Wang, Co-Founder, CEO & Director (Age 44)
  • Dr. Hai Yan, Co-Founder, Chief Scientific Officer & Director (Age 53)
  • Mr. Ce Xu, Chief Financial Officer (Age 39)
  • Mr. Ying Hong, Chief Operating Officer (Age 49)
  • Dr. Yuchen Jiao M.D., Ph.D., Chief Technology Officer (Age 43)
  • Dr. Yun-Fu Hu Ph.D., Chief Medical Officer (Age 58)

Who are some of Genetron's key competitors?

When did Genetron IPO?

(GTH) raised $162 million in an IPO on Friday, June 19th 2020. The company issued 13,000,000 shares at $11.50-$13.50 per share. Credit Suisse and CICC served as the underwriters for the IPO and BTIG and Canaccord Genuity were co-managers.

What is Genetron's stock symbol?

Genetron trades on the NASDAQ under the ticker symbol "GTH."

Who are Genetron's major shareholders?

Genetron's stock is owned by many different institutional and retail investors. Top institutional shareholders include Victory Capital Management Inc. (0.08%).

Which institutional investors are selling Genetron stock?

GTH stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc..

How do I buy shares of Genetron?

Shares of GTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genetron's stock price today?

One share of GTH stock can currently be purchased for approximately $14.35.

How much money does Genetron make?

Genetron has a market capitalization of $1.28 billion and generates $65.06 million in revenue each year.

How many employees does Genetron have?

Genetron employs 799 workers across the globe.

What is Genetron's official website?

The official website for Genetron is www.genetronhealth.com.

Where are Genetron's headquarters?

Genetron is headquartered at 1-2/F BUILDING 11 ZONE 1 CHANGPING DISTRICT, BEIJING F4, 102206.

How can I contact Genetron?

Genetron's mailing address is 1-2/F BUILDING 11 ZONE 1 CHANGPING DISTRICT, BEIJING F4, 102206. The company can be reached via phone at 86 10 5090 7500 or via email at [email protected]


This page was last updated on 8/4/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.